10-K: Canopy Growth Reports Deepened Losses Amid Strategic Restructuring and U.S. Cannabis Expansion

Canopy Growth Corporation reported a significant increase in net loss for fiscal year 2025, reaching C$604.1 million, despite improvements in gross margin and a reduction in Adjusted EBITDA loss, as the company continues its strategic shift towards an asset-right model and U.S. market entry.

Summary

• Canopy Growth reported a net loss from continuing operations of C$604.1 million for fiscal year 2025, a 25% increase from C$483.7 million in fiscal year 2024.
• The company's gross margin percentage improved to 30% in fiscal 2025, up from 27% in fiscal 2024, primarily due to cost savings and a shift to higher-margin medical sales in Canada.
• Adjusted EBITDA loss decreased significantly to C$23.5 million in fiscal 2025, compared to C$58.9 million in fiscal 2024, driven by reduced selling, general, and administrative expenses.
• Net revenue for fiscal 2025 was C$269.0 million, a 9% decrease from C$297.1 million in fiscal 2024, mainly due to the divestiture of This Works and lower Canadian adult-use cannabis sales, partially offset by growth in Canadian medical cannabis and Storz & Bickel.
• The company successfully reduced its total debt outstanding by 49% to C$304.1 million as of March 31, 2025, from C$597.2 million as of March 31, 2024, and extended the maturity date of its Credit Facility to September 18, 2027.
• Canopy USA, the company's U.S.-domiciled holding company, completed the acquisitions of 100% of Wana, approximately 77% of Jetty, and 100% of Acreage during fiscal 2025.
• The company deconsolidated the financial results of Canopy USA as of April 30, 2024, and now accounts for its interest as an equity method (fair value) investment.
• Canopy Growth utilized At-The-Market (ATM) equity programs, selling 71,044,862 common shares for C$347.1 million (US$250 million) under the June 2024 ATM Program and 23,169,358 common shares for C$38.3 million (US$26.7 million) under the February 2025 ATM Program.
• Luc Mongeau was appointed as the new CEO effective January 6, 2025, succeeding David Klein, who transitioned to a Special Advisor role.
• The company is subject to ongoing class action lawsuits and an SEC investigation related to financial reporting matters concerning the BioSteel business unit.

Sentiment

Score: 4

Explanation: The company shows operational improvements (gross margin, Adjusted EBITDA) and has made significant strides in debt reduction and strategic U.S. market entry. However, the substantial increase in net loss, ongoing legal/regulatory challenges, and the significant financial risks associated with its Canopy USA investments (especially Acreage's going concern status) indicate a challenging financial position and high uncertainty.

Positives

• Gross margin percentage improved to 30% in fiscal 2025 from 27% in fiscal 2024, reflecting benefits from cost savings and a shift to higher-margin medical sales in Canada.
• Adjusted EBITDA loss significantly decreased to C$23.5 million in fiscal 2025, a 60% improvement from C$58.9 million in fiscal 2024, driven by reduced operating expenses.
• Total debt outstanding was reduced by C$293 million (49%) to C$304.1 million as of March 31, 2025, and the maturity date of the Credit Facility was extended to September 18, 2027.
• Canadian medical cannabis net revenue increased by 16% to C$77.0 million in fiscal 2025, due to larger average order sizes and a broader product assortment.
• Storz & Bickel revenue grew by 4% to C$73.4 million in fiscal 2025, driven by strong sales in Germany and the UK, and the success of the new Venty portable vaporizer.
• Canopy USA completed key acquisitions of 100% Wana, approximately 77% Jetty, and 100% Acreage, establishing a foundation for participation in the U.S. cannabis market.
• The company believes it has alleviated substantial doubt about its ability to continue as a going concern due to recent financial actions and strategic plans.

Negatives

• Net loss from continuing operations increased by 25% to C$604.1 million in fiscal 2025, primarily due to increased fair value losses on Canopy USA related assets.
• Net revenue decreased by 9% to C$269.0 million in fiscal 2025, impacted by the divestiture of This Works and lower Canadian adult-use cannabis sales.
• Canadian adult-use cannabis net revenue decreased by 15% to C$78.8 million, primarily due to lower sales volumes and increased price competition.
• The company recognized C$400.2 million in fair value decreases related to its Canopy USA investments and other financial assets in fiscal 2025.
• Acreage Holdings, Inc., a key Canopy USA asset, expressed doubt about its ability to continue as a going concern in its last publicly available financial statements, posing a significant risk to Canopy Growth's U.S. strategy and investment.
• Acreage is currently in default under the Second ARCA, and while lenders have agreed to forebear remedies until June 1, 2025, the company may lose its C$157.7 million (US$109.6 million) investment in Acquired Debt if Acreage cannot satisfy its obligations.
• The company is subject to ongoing regulatory investigations and class action lawsuits related to financial reporting matters concerning the BioSteel business unit and alleged misrepresentations regarding Claybourne product launch costs and gross margins.

Risks

• The company may not be able to achieve or maintain profitability and may continue to incur losses in the future, having experienced recurring losses from operations and negative operating cash flow since fiscal 2019.
• The company is in the early stages of developing global infrastructure in a new industry, subjecting it to risks common in developing companies, including under-capitalization and limitations with personnel and resources.
• The company may be required to write down intangible assets, including goodwill, due to impairment, which could materially adversely affect its financial condition and results of operations.
• The anticipated benefits of the strategy involving Canopy USA may not be realized, and the fair value of the equity method investment in Canopy USA is volatile, having declined by 78% from June 30, 2024, to March 31, 2025.
• There is limited long-term data on the efficacy, side effects, and safety of cannabis products, and future research may dispute current beliefs, leading to decreased demand, litigation, or regulatory actions.
• The company is subject to extensive and rapidly developing regulations and licensing requirements in all jurisdictions, and failure to comply could result in penalties, operational restrictions, or license revocations.
• The production and distribution of products are subject to disruption, agricultural risks (e.g., crop failure), and the risk of third-party suppliers and distributors not performing their obligations.
• The company faces highly competitive conditions from both licensed and illegal market participants, which could impact market share and pricing.
• The ongoing regulatory investigation and inquiry related to the BioSteel Review could have a material adverse effect on the company, its stock price, and its ability to raise capital.
• The Trusts total ownership interest in Canopy USA is not quantifiable, and the Trust may have significant ownership and influence over Canopy USA, potentially diluting Canopy Growth shareholders.
• The company is unable to control Canopy USA, meaning Canopy USA's board could take actions contrary to Canopy Growth's or its shareholders' interests.
• The controversy surrounding vapes and vaporizer products and government regulations may adversely affect the market for these products and expose the company to litigation and additional regulation.
• Cannabis remains a controlled substance under U.S. federal law, posing risks of federal enforcement against U.S. cannabis operations and potential loss of investment.
• The company is subject to certain restrictions by the TSX and Nasdaq, which may constrain its ability to expand in the United States and could lead to delisting if not complied with.
• Federal law in the United States may restrict the company's ability to bank with certain institutions, repatriate funds to Canada, or pay dividends to shareholders due to cannabis's federal illegality.
• Any rescheduling of U.S. Schedule I cannabis to Schedule III would have an uncertain impact on the business, potentially benefiting competitors more or leading to significant stock price volatility.
• The Canadian excise duty framework significantly increases the cost of cannabis to consumers, affecting profitability and competitiveness.
• Failure to establish and maintain effective internal control over financial reporting may result in inaccurate financial reporting, loss of investor confidence, and adverse effects on stock price.
• The company is vulnerable to third-party transportation risks, including security breaches and rising costs.
• The inability of customers or suppliers to meet financial or contractual obligations could disrupt the supply chain and result in financial losses.
• Increased rates of inflation, particularly on wages and supplier pricing, could adversely affect results if not offset by higher prices or cost savings.
• Cannabis cultivation operations are vulnerable to rising energy costs and dependent on key inputs, which could materially adversely affect financial results.
• Unfavorable publicity or negative consumer perception regarding cannabis or the company's products could harm demand and reputation.
• The company is subject to liability from fraudulent or illegal activity by employees, contractors, and consultants.
• Adverse changes or developments affecting production facilities, including security breaches or crop failure, could materially adversely affect operations.
• The majority of the company's assets are capital stock of material subsidiaries, making investors subject to risks attributable to those subsidiaries.
• The company is subject to various privacy and data security laws and contractual obligations, and breaches could lead to significant fines, penalties, and reputational harm.
• The company may be subject to product liability claims if products are alleged to cause injury or illness, or are incorrectly labeled.
• Reliance on third-party testing and analytical methods, which are still being standardized, could lead to consumer confusion, litigation, or regulatory enforcement.
• The company may be required to divest or restructure certain interests if they violate applicable laws or regulations, potentially on unfavorable terms.
• Fluctuations in wholesale and retail prices could result in earnings volatility due to factors beyond the company's control.
• The Credit Facility contains restrictive covenants that may limit operating flexibility and require compliance with financial covenants.
• Inability to attract or retain skilled labor and personnel, or obtain adequate equipment, parts, and components, could adversely affect operations.
• Exposure to counterparty and liquidity risks may impact the ability to obtain loans and other credit facilities on favorable terms.
• Changes in tax and accounting requirements or their interpretations could adversely affect financial results.
• Challenging global economic conditions, including tariffs and trade protection measures, could negatively impact the business.
• Natural disasters, pandemic outbreaks, boycotts, geopolitical events, or acts of terrorism could adversely affect operations and financial results.
• The business may be negatively affected by climate change, weather conditions, and the availability of natural resources.
• Evolving corporate governance and public disclosure regulations and expectations, particularly regarding ESG matters, could increase compliance costs and expose the company to risks.
• Inability to obtain or maintain adequate insurance coverage at acceptable rates could expose the company to significant liabilities.

Future Outlook

Canopy Growth aims to achieve sustainable profitability by focusing on its global medical cannabis platform, optimizing its Canadian adult-use cannabis business through powerhouse brands and efficient distribution, and leveraging its disciplined asset-right model. The company anticipates unparalleled exposure to the expanding U.S. cannabis market through its unconsolidated investment in Canopy USA, which has acquired leading U.S. cannabis brands Wana, Jetty, and Acreage. Future growth is contingent on successful product innovation, market execution, and navigating evolving regulatory landscapes, particularly in the U.S. regarding cannabis rescheduling.

Management Comments

• "Our vision is to unleash the power of cannabis to improve lives."
• "We are a collective of dynamic and engaged leaders, united by a passion for cannabis, focused on delighting our consumers and medical cannabis patients while creating value for our stakeholders and one another."
• "Our overall strategy is anchored in our commitment to building beloved consumer brands within an asset-right operating model, which focuses on driving efficiency for the greatest return on asset investment while owning the core capabilities that are critical to long-term sustainable success."
• "We believe that this will enable us to compete more effectively, and lead, in today's rapidly evolving market."
• "Our unwavering commitment to the safety and effectiveness of our products is a critical strategic imperative which also helps differentiate us in the growing cannabis market."
• "Vaporization is a consumption method that aligns with the desires of several of our medical cannabis patients and adult-use consumers."
• "The heart of our business is in North America with our roots in Canada and investments in the U.S."
• "As markets continue to evolve, we believe the role of brands will become more prominent in consumers desire for trustworthy products that deliver quality and consistency of experience."
• "Our objective is to excel at our own internal manufacturing capabilities by making selective investments in assets that will accelerate returns and secure long-term sustainable profitability."
• "Unlike other cannabis businesses, our investment in Canopy USA provides a unique opportunity to maximize the value of our previously-held conditional U.S. THC investments."
• "Canopy USA's powerhouse brands, Wana and Jetty, establish a foundation for us to participate in the world's largest and fastest growing cannabis market and to offer our shareholders unique exposure to this market's growth."
• Luc Mongeau's appointment as CEO reflects a careful alignment with Canopy Growth's strategic priorities, leveraging his expertise in leading complex organizations through transformation, particularly in CPG and digital commerce, to drive continued expansion and focus on profitability.

Industry Context

The cannabis industry continues to be characterized by rapid regulatory evolution, particularly in the U.S. where federal illegality conflicts with state-level legalization, creating complex investment and operational challenges. The ongoing discussion around rescheduling cannabis from Schedule I to Schedule III under the CSA, while potentially beneficial, introduces uncertainty regarding future regulatory controls and competitive dynamics. In Canada, the market faces intense competition from both licensed producers and the illegal market, alongside evolving provincial regulations and excise duties impacting profitability. The global medical cannabis market is expanding, with increasing demand for EU-GMP certified products. The company's strategy to focus on an 'asset-right' model and leverage third-party sourcing reflects a broader industry trend towards efficiency and cost optimization in a maturing yet volatile market.

Comparison to Industry Standards

• The company uses two distinct peer groups (Canadian consumer-focused and U.S. CPG/Pharmaceuticals, including cannabis companies) for benchmarking executive compensation, aiming for the 50th percentile of relevant publicly-traded peers.
• The document does not provide specific financial performance comparisons to named comparable companies or projects within the cannabis industry or global benchmarks beyond the executive compensation context.

Management Changes

Corporate Governance

Legal Proceedings

• The company is a defendant in a putative class action lawsuit (Dziedziejko v. Canopy Growth Corporation et al.) in the Ontario Superior Court of Justice, alleging misrepresentations in disclosures and failure to remedy internal control deficiencies, seeking unspecified damages.
• Another putative class action (Asmaro v. Canopy Growth Corporation et al.) was commenced in the Supreme Court of British Columbia, alleging misrepresentations in disclosures and seeking unspecified damages.
• The company is the subject of an ongoing investigation by the SEC as a result of voluntarily self-reporting financial reporting matters related to the BioSteel business unit, which could result in material adverse impacts including financial penalties.
• A payment guarantor under a share purchase agreement commenced a counterclaim against the company in arbitration, seeking C$6,399,700 in general damages and C$1,000,000 in aggravated damages for alleged breaches of the agreement.
• A putative class action (Baron v. Canopy Growth Corporation et al.) was commenced in the U.S. District Court Eastern District of New York, alleging violations of U.S. federal securities laws due to alleged false/misleading statements regarding Claybourne pre-rolled joint production costs, Storz & Bickel indirect costs, and overstated efficacy of cost reduction measures/health of gross margins.

Related Party Transactions

• On April 18, 2024, Greenstar Canada Investment Limited Partnership (Greenstar) and CBG Holdings LLC (CBG), indirect wholly-owned subsidiaries of Constellation Brands, Inc. (CBI), exchanged all 17,149,925 Canopy Shares they collectively held for 17,149,925 Exchangeable Shares for no consideration (CBI Exchange).
• Concurrently with the CBI Exchange, Greenstar converted approximately C$81.2 million of the principal amount of a C$100 million promissory note (CBI Note) into 9,111,549 Exchangeable Shares (Note Exchange), with all accrued but unpaid interest and the remaining principal cancelled and forgiven.
• As a result of the CBI Exchange and Note Exchange, the CBI Group no longer holds any Canopy Shares but holds 26,261,474 Exchangeable Shares, representing approximately 12.4% of outstanding Canopy Shares on a non-diluted basis (assuming conversion).
• The Investor Rights Agreement and other commercial arrangements between Canopy Growth and CBI were terminated on April 18, 2024, following the CBI Exchange, removing CBI's governance rights in Canopy Growth.
• Upon deconsolidation of Canopy USA, intercompany loans (Elevate loan) between subsidiaries became a related party loan recognized at fair value, with Canopy USA delivering guarantees for these obligations on December 9, 2024. As of March 31, 2025, the aggregate principal and interest owing on the Elevate loan to Canopy is C$248.5 million (US$172.7 million) and C$50.1 million (US$34.8 million), respectively.

Stakeholder Impact

• **Shareholders:** Experience significant dilution from ATM programs and other share issuances (e.g., Acreage acquisition). The market price of Canopy Shares has been highly volatile and declined significantly, impacting shareholder returns. The shift to non-voting Exchangeable Shares for CBI Group impacts their direct voting influence. Ongoing legal proceedings and SEC investigation pose risks to shareholder value.
• **Employees:** Subject to restructuring actions and cost savings programs, including headcount reductions (960 total employees as of March 31, 2025, down from 1,029). Retention awards were provided to key executives to ensure stability during CEO transition. The company focuses on employee development, inclusive environment, and well-being resources.
• **Customers:** Benefit from a broader portfolio of cannabis products, including new innovative formats and high-quality medical cannabis. The company aims to enhance distribution and customer care, particularly for insured medical patients. However, price competition in the adult-use market may affect product availability or pricing strategies.
• **Suppliers:** The company is optimizing its operating footprint and leveraging local/regional suppliers for raw materials. Reliance on third-party manufacturers and distributors means their performance and financial health can impact the company's operations. The company faces challenges with certain financially distressed customers/suppliers.
• **Creditors:** The company has significantly reduced its debt and extended maturity dates, improving its financial stability and ability to meet obligations. However, Acreage's default on its debt obligations, where the company is a subordinate lender, poses a risk of non-repayment of a significant investment.

Next Steps

• Continue to fuel demand for EU-GMP certified medical grade cannabis internationally with supply from within Europe and from the Canadian EU-GMP certified facility in Kincardine, Ontario.
• Maximize existing routes to market to further execution on international growth plans, leveraging cannabis expertise and established medical brands.
• Continue to push for more impactful product innovations for global vaporization through Storz & Bickel, focusing on addressing consumer needs in the North American market.
• Continue investing in brands (Tweed, Claybourne, HiWay, 7ACRES, Twd., Wana, Deep Space) to strengthen market leadership and consumer relationships in the Canadian adult-use market.
• Focus efforts on product categories with the highest and most tangible profit opportunities that align with customer needs and consumer desires.
• Significantly optimize wholesale capabilities to ensure broadest distribution in highest profit geographies.
• Excel at internal manufacturing capabilities by making selective investments in assets that will accelerate returns and secure long-term sustainable profitability.
• Continue to leverage local and/or regional suppliers for raw materials to complement owned operations.
• Continually and consistently seek to optimize operating footprint to achieve profitability and foster growth while retaining commitment to product quality and supply chain integrity.
• Canopy USA will continue full integration of Acreage under a new leadership team.
• Continue to evaluate different strategies and pursue additional actions to further increase liquidity position, including cost-savings and seeking additional financing from public and private markets.
• Monitor political developments and the formal rulemaking process regarding the potential reclassification of marijuana from Schedule I to Schedule III by the DEA.
• Continue to vigorously defend against ongoing class action lawsuits and cooperate fully with the SEC investigation related to the BioSteel Review.

Key Dates

Recommendation

Keywords

Cannabis, Marijuana, THC, CBD, Medical Cannabis, Adult-Use Cannabis, Vaporizers, SEC Filing, 10-K, Financial Results, Corporate Governance, Risk Management, Strategic Acquisitions, Debt Reduction, Canopy USA, Storz & Bickel, Acreage Holdings, Wana, Jetty, Canada Cannabis, International Markets, Regulatory Compliance, Going Concern, Capital Raise, ATM Program, Share Consolidation, Excise Tax, Supply Chain, Intellectual Property, Product Liability, Litigation, Executive Compensation